Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Curcumin in Critically Ill Patients With Sepsis
NCT07436130Recruiting
- Sponsor
- Hospital Civil de Guadalajara
- Start
- Mar 2026
- Primary completion
- Mar 2027
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in sepsis comparing Curcumin + Standard of Care with Placebo + Standard of Care (2 arms). Primary endpoints: Interleukin-6 at Day 10, Interleukin-1 beta at Day 10 and 1 more. Started Mar 2026; status: recruiting.
02
Drugs
curcumin
03
Conditions
sepsis
Beyond the preview
Go deeper on NCT07436130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07436130.